Individuals aged 65 years and older are at an increased risk for more detrimental effects of influenza.
This program helps clinicians optimize influenza immunization for adults aged ≥65 years old. The program will review the influenza burden in this population, the types of adverse outcomes experienced by older adults, and how to prevent adverse outcomes with vaccination.
Using a case study, the program will also compare the different vaccines indicated for this population and discuss the National Advisory Committee on Immunization (NACI) and Advisory Committee on Immunization Practices (ACIP) recommendations as well as the available real-world vaccine effectiveness data for influenza vaccines in adults ≥65 years old.
This program is made possible through educational support from CSL Seqirus.